Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
“A and B”:
Direct fabrication of large micropatterned single crystals. p1205 21 Feb 2003. (news): Academy plucks best biophysicists from a sea of mediocrity. p994 14 Feb 2003.
View via Publisher
Outcomes among 562 recipients of placental-blood transplants from unrelated donors.
TLDR
Placental blood is a useful source of allogeneic hematopoietic stem cells for bone marrow reconstitution and is associated with the severity of GVHD, type of leukemia, and stage of the disease.
View on PubMed
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
TLDR
It is demonstrated that recombinant human erythropoietin is effective, can eliminate the need for transfusions with their risks of immunologic sensitization, infection, and iron overload, and can restore the hematocrit to normal in many patients with the anemia of end-stage renal disease.
View on PubMed
Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.
TLDR
Almost all the hematopoietic colony-forming cells present in PCB units can be recovered in a uniform volume of 20 ml by using rouleaux formation induced by hydroxyethyl starch and centrifugation to reduce the bulk of erythrocytes and plasma and, thus, concentrate leukocytes.
View on PubMed
Hepatocyte nuclear factor 4α controls the development of a hepatic epithelium and liver morphogenesis
TLDR
It is reported that hepatocyte nuclear factor 4α (Hnf4α) is essential for morphological and functional differentiation of hepatocytes, accumulation of hepatic glycogen stores and generation of a hepatic epithelium, and the morphogenetic parameters controlled by Hnf 4α in hepatocytes are essential for normal liver architecture, including the organization of the sinusoidal endothelium.
View on Nature
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease
TLDR
The use of ESAs and other agents to treat anemia in CKD and methods for Guideline Development suggest that red cell transfusion is a viable treatment option.
View via Publisher
Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.
TLDR
Both depressed platelet production and increased platelet clearance by the liver and spleen contribute to the thrombocytopenia of AITP.
View on PubMed
Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease aims to provide guidance on diagnosis, evaluation, management and treatment…
View via Publisher
How we diagnose and treat iron deficiency anemia
TLDR
The preponderance of published evidence suggests IV iron therapy is underutilized and it is believed that IV iron should be moved forward in the treatment of ID and iron deficiency anemia (IDA).
View on Wiley
Iron metabolism in man.
TLDR
An overview of the current understanding of iron metabolism, the recently discovered regulators of iron trafficking, and a focus on the effects of inflammation on the process is provided.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License